Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177289 | 1.00 | ADRB3 (0.42) | ADRB3ADRA1AADRB2ADRB1POLB | |
| SCHEMBL5195520 | 0.81 | KIF11 (0.41) | ADRB3ADRA1APOLB | |
| SCHEMBL5195514 | 0.81 | KIF11 (0.41) | ADRB3ADRA1APOLB | |
| SCHEMBL5195251 | 0.76 | ADRB3 (0.55) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5195244 | 0.76 | ADRB3 (0.55) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5195868 | 0.76 | ADRB3 (0.51) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5196608 | 0.76 | ADRB3 (0.51) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5195866 | 0.76 | ADRB3 (0.51) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5196619 | 0.76 | ADRB3 (0.51) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL5196046 | 0.73 | ADRB3 (0.52) | ADRB3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304443-B2 | Indazole derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152265-A1 | INDAZOLE DERIVATIVES | ADRB3, INSR, ADRB1 | ADRB3 1/4885ADRA1A 9/4885ADRB2 10/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | ADRB3 5/4885ADRA1A 3/4885ADRB2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.